Evidence map›Paper›PMID 34683850›Full record

ArticlePharmaceutics2021

Albumin-EDTA-Vanadium Is a Powerful Anti-Proliferative Agent, Following Entrance into Glioma Cells via Caveolae-Mediated Endocytosis.

Itzik Cooper, Orly Ravid, Daniel Rand, Dana Atrakchi, Chen Shemesh, Yael Bresler, Gili Ben-Nissan, Michal Sharon, Mati Fridkin, Yoram Shechter

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Itzik CooperThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat-Gan 52620, Israel.
Orly RavidThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat-Gan 52620, Israel.
Daniel RandThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat-Gan 52620, Israel.ORCID 0000-0002-4659-9966
Dana AtrakchiThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat-Gan 52620, Israel.
Chen ShemeshThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat-Gan 52620, Israel.
Yael BreslerThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat-Gan 52620, Israel.
Gili Ben-NissanDepartment of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot 76100, Israel.
Michal SharonDepartment of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot 76100, Israel.
Mati FridkinDepartment of Organic Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel.
Yoram ShechterDepartment of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot 76100, Israel.
Sheba Medical Center · ILWeizmann Institute of Science · ILReichman University · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human serum albumin (HSA) is efficiently taken up by cancer cells as a source of carbon and energy. In this study, we prepared a monomodified derivative of HSA covalently linked to an EDTA derivative and investigated its efficacy to shuttle weakly anti-proliferative EDTA associating ligands such as vanadium, into a cancer cell line. HSA-S-MAL-(CH

Indexed as

albumincancerconjugatesprodrugvanadium

Identifiers

PMID34683850
PMCPMC8540012
OpenAlexW3202406870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.